# A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

> **NCT04158258** · — · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 2907 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Trastuzumab
- **DRUG:** Ado-trastuzumab emtamsine
- **DRUG:** Pertuzumab
- **DRUG:** Atezolizumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04158258
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-21
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 2907 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158258, "A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04158258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*